GDRX vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
GDRX exhibits a fragile financial profile with a Piotroski F-Score of 4/9, indicating only marginal stability. The stock is currently trading at $2.16, which is a premium to its Graham Number ($1.91) and significantly above its growth-based intrinsic value ($0.63). Fundamental decay is evident through negative YoY revenue (-1.90%) and earnings growth (-9.70%), compounded by a streak of four consecutive earnings misses. With a 5-year price collapse of 94.7% and bearish insider sentiment, the data suggests a company in a structural decline.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
GDRX vs MRK: Head-to-Head Comparison
This page compares GoodRx Holdings, Inc. (GDRX) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.